Pharma Commercial Mock
← All views
Competitive intelligence

CI feed

Conference abstracts + payer decisions interleaved chronologically — the CI team aims to publish a structured briefing within 48 hours of any high-relevance event landing here.

16 items in window · 16 high-relevance

type:allabstractspayer decisionsrelevance:allhighmediumlow
  1. Congresshighembargo lifts in 1d
    Jun 1, 2026, 4:00 PM
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    Median OS 33.8 months. HR 0.8 (95% CI 0.71–0.89). No new safety signals identified.
    Kisqali () · NovartisHR+ breast cancerMONALEESA-38 · NCT60056504Poster Discussion Session
    OS
    33.8 months
    HR 0.8 (0.71-0.89)
    PFS
    22.8 months
    HR 0.77 (0.69-0.86)
    ORR
    77.9 percent
  2. Congresshighembargo lifts in 1d
    Jun 1, 2026, 4:15 PM
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    Median OS 29.4 months. HR 0.85 (95% CI 0.76–0.94). Grade ≥3 AEs consistent with prior reports.
    Enhertu () · Daiichi SankyoNSCLCDESTINY-Breast-376 · NCT30918589Poster Session
    OS
    29.4 months
    HR 0.85 (0.76-0.94)
    PFS
    7.2 months
    HR 0.89 (0.8-0.91)
    ORR
    50.6 percent
  3. Congresshighembargo lifts in 2d
    Jun 2, 2026, 3:45 PM
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-349
    Median OS 37.6 months. HR 0.68 (95% CI 0.56–0.8). No new safety signals identified.
    Ibrance () · PfizerHR+ breast cancerPALOMA-349 · NCT90598054Oral Abstract Session
    OS
    37.6 months
    HR 0.68 (0.56-0.8)
    PFS
    23.6 months
    HR 0.67 (0.53-0.78)
    ORR
    78 percent
  4. Congresshighembargo lifts in 2d
    Jun 2, 2026, 4:00 PM
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-312 study)
    Median OS 28.5 months. HR 0.68 (95% CI 0.55–0.81). Grade ≥3 AEs consistent with prior reports.
    Tagrisso () · AstraZenecaNSCLCFLAURA-312 · NCT74476517Rapid Oral Abstract Session
    OS
    28.5 months
    HR 0.68 (0.55-0.81)
    PFS
    8.8 months
    HR 0.69 (0.54-0.82)
    ORR
    44.2 percent
  5. Congresshighembargo lifts in 2d
    Jun 2, 2026, 8:30 PM
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    Median OS 35.6 months. HR 0.7 (95% CI 0.62–0.78). Grade ≥3 AEs consistent with prior reports.
    Kisqali () · NovartisHR+ breast cancerMONALEESA-190 · NCT77693036Poster Session
    OS
    35.6 months
    HR 0.7 (0.62-0.78)
    PFS
    20.5 months
    HR 0.74 (0.66-0.81)
    ORR
    55.5 percent
  6. Congresshighembargo lifts in 3d
    Jun 3, 2026, 3:30 PM
    FLAURA-898: Tagrisso (osimertinib) 2L in NSCLC
    Median OS 22.5 months. HR 0.76 (95% CI 0.66–0.86). Grade ≥3 AEs consistent with prior reports.
    Tagrisso () · AstraZenecaNSCLCFLAURA-898 · NCT65454622Poster Session
    OS
    22.5 months
    HR 0.76 (0.66-0.86)
    PFS
    10.5 months
    HR 0.76 (0.68-0.84)
    ORR
    59.6 percent
  7. Congresshighembargo lifts in 3d
    Jun 3, 2026, 3:45 PM
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-410 study)
    Median OS 36.7 months. HR 0.9 (95% CI 0.77–0.99). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-410 · NCT12503018Oral Abstract Session
    OS
    36.7 months
    HR 0.9 (0.77-0.99)
    PFS
    22.3 months
    HR 0.93 (0.8-0.99)
    ORR
    58.8 percent
  8. Congresshighembargo lifts in 4d
    Jun 4, 2026, 2:00 PM
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-881
    Median OS 29.3 months. HR 0.6 (95% CI 0.51–0.69). No new safety signals identified.
    Opdivo () · Bristol-Myers SquibbNSCLCCheckMate-881 · NCT08001951Poster Session
    OS
    29.3 months
    HR 0.6 (0.51-0.69)
    PFS
    7.4 months
    HR 0.61 (0.51-0.72)
    ORR
    60 percent
  9. Congresshighembargo lifts in 4d
    Jun 4, 2026, 4:30 PM
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-190
    Median OS 12.7 months. HR 0.83 (95% CI 0.72–0.94). Grade ≥3 AEs consistent with prior reports.
    Imfinzi () · AstraZenecabiliary tractPACIFIC-190 · NCT97449766Poster Session
    OS
    12.7 months
    HR 0.83 (0.72-0.94)
    PFS
    7.5 months
    HR 0.83 (0.69-0.97)
    ORR
    34.7 percent
  10. Congresshighembargo lifts in 4d
    Jun 4, 2026, 5:00 PM
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-645
    Median OS 22.4 months. HR 0.6 (95% CI 0.5–0.7). Grade ≥3 AEs consistent with prior reports.
    Keytruda () · MerckNSCLCKEYNOTE-645 · NCT22264892Poster Discussion Session
    OS
    22.4 months
    HR 0.6 (0.5-0.7)
    PFS
    7.7 months
    HR 0.64 (0.49-0.67)
    ORR
    45.7 percent
  11. Congresshighembargo lifts in 4d
    Jun 4, 2026, 7:45 PM
    Quality of life outcomes with Keytruda in patients with NSCLC
    Median OS 25.6 months. HR 0.79 (95% CI 0.7–0.88). Grade ≥3 AEs consistent with prior reports.
    Keytruda () · MerckNSCLCKEYNOTE-433 · NCT65945184Poster Session
    OS
    25.6 months
    HR 0.79 (0.7-0.88)
    PFS
    11.7 months
    HR 0.77 (0.66-0.89)
    ORR
    61.9 percent
  12. Congresshighembargo lifts in 5d
    Jun 5, 2026, 2:15 PM
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    Median OS 38.2 months. HR 0.9 (95% CI 0.8–0.99). No new safety signals identified.
    Ibrance () · PfizerHR+ breast cancerPALOMA-223 · NCT98838794Oral Abstract Session
    OS
    38.2 months
    HR 0.9 (0.8-0.99)
    PFS
    27.1 months
    HR 0.86 (0.8-0.95)
    ORR
    57.2 percent
  13. Congresshighembargo lifts in 5d
    Jun 5, 2026, 5:00 PM
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    Median OS 38.9 months. HR 0.58 (95% CI 0.47–0.69). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-149 · NCT32526973Oral Abstract Session
    OS
    38.9 months
    HR 0.58 (0.47-0.69)
    PFS
    19.4 months
    HR 0.6 (0.48-0.7)
    ORR
    74.7 percent
  14. Congresshighembargo lifts in 5d
    Jun 5, 2026, 5:30 PM
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-419 study)
    Median OS 14.9 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.
    Imfinzi () · AstraZenecaSCLCPACIFIC-419 · NCT88358487Oral Abstract Session
    OS
    14.9 months
    HR 0.83 (0.74-0.92)
    PFS
    6.1 months
    HR 0.81 (0.76-0.89)
    ORR
    63 percent
  15. Congresshighembargo lifts in 5d
    Jun 5, 2026, 9:30 PM
    MONARCH-789: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    Median OS 37.2 months. HR 0.87 (95% CI 0.75–0.99). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-789 · NCT81284428Rapid Oral Abstract Session
    OS
    37.2 months
    HR 0.87 (0.75-0.99)
    PFS
    24.7 months
    HR 0.85 (0.74-0.99)
    ORR
    58.8 percent
  16. Congresshighembargo lifts in 5d
    Jun 5, 2026, 10:00 PM
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-449
    Median OS 23.5 months. HR 0.86 (95% CI 0.75–0.97). No new safety signals identified.
    Tecentriq () · RocheTNBCIMpower-449 · NCT18767167Poster Session
    OS
    23.5 months
    HR 0.86 (0.75-0.97)
    PFS
    9.9 months
    HR 0.87 (0.73-0.98)
    ORR
    50.8 percent